KNSANASDAQHealthcare

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$93.86

+6.25%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze KNSA free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+19.2%

3 months

+22.6%

6 months

+60.2%

1 year

+143.0%

Year to date

+127.5%

52-week range

$37.92 – $97.56

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$7.37B

P/E

67.3

P/B

10.4

P/S

7.8

Revenue

$945.96M

Net income

$109.57M

Diluted EPS

1.31

Gross margin

90.20%

Net margin

11.60%

Return on equity

17.30%

Total debt

$7.88M

Cash

$81.66M

Free cash flow

$197.2M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$285.97M	$47.35M	90.30%	16.60%	$47.37M
Jun 30, 2026	$243.6M	$25.43M	90.30%	10.40%	$46.53M
Mar 31, 2026	$214.27M	$22.59M	90.30%	10.50%	$50.04M
Dec 31, 2025	$202.13M	$14.2M	89.60%	7.00%	$53.26M
Sep 30, 2025	$180.86M	$18.44M	88.80%	10.20%	$33.01M
Jun 30, 2025	$156.8M	$17.83M	88.10%	11.40%	$27.93M
Mar 31, 2025	$137.79M	$8.54M	87.00%	6.20%	$22.23M
Dec 31, 2024	$122.54M	-$8.89M	85.40%	-7.30%	$18.58M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent KNSA news

All market news

Stock Titan·Oct 31, 202648 signal

An officer proposes selling Kiniksa (KNSA) shares, including 97,572 from an option exercise.

Kiniksa Pharmaceuticals International, plc officer Ross Moat has proposed selling 103,585 Class A ordinary shares, valued at approximately $9.75 million, through Charles Schwab & Co., Inc. The proposed sale, with an approximate date of October 30, 2026, includes shares from two restricted stock lapses and a significant portion (97,572 shares) from an employee stock option exercise. This Form 144 filing provides details on the origin of the shares and the regulatory context of the sale.

Original source